 |
Previous Article | Next Article 
Volume 16, Number 9,
Issue of May 1, 1996
pp. 3104-3111
Copyright ©1996 Society for Neuroscience
Mouse Model of Hyperkinesis Implicates SNAP-25 in Behavioral
Regulation
Received Dec. 20, 1995; revised Feb. 1, 1996; accepted Feb. 9, 1996.
Ellen J. Hess1,
Katherine A. Collins2, and
Michael C. Wilson2
1 Department of Neuroscience and Anatomy, The
Pennsylvania State University College of Medicine, Hershey Medical
Center, Hershey, Pennsylvania 17033, and 2 Department of
Neuropharmacology, The Scripps Research Institute, La Jolla,
California 92037
Although hyperkinesis is expressed in several neurological
disorders, the biological basis of this phenotype is unknown. The mouse
mutant coloboma (Cm/+) exhibits profound spontaneous
locomotor hyperactivity resulting from a deletion mutation. This
deletion encompasses several genes including Snap, which
encodes SNAP-25, a nerve terminal protein involved in neurotransmitter
release. Administration of amphetamine, a drug that acts
presynaptically, markedly reduced the locomotor activity in coloboma
mice but increased the activity of control mice implicating presynaptic
function in the behavioral abnormality. In contrast, the
psychostimulant methylphenidate increased locomotor activity in both
coloboma and control mice. When a transgene encoding SNAP-25 was bred
into the coloboma strain to complement the Snap deletion,
the hyperactivity expressed by these mice was rescued, returning these
corrected mice to normal levels of locomotor activity. These results
demonstrate that the hyperactivity exhibited by these mice is the
result of abnormalities in presynaptic function specifically
attributable to deficits in SNAP-25 expression.
Key words:
hyperactivity;
ADHD;
locomotor activity;
amphetamine;
methylphenidate;
transgenic;
SNAP-25;
mouse mutant;
psychostimulant;
coloboma
This article has been cited by other articles:

|
 |

|
 |
 
A. F. Jeans, P. L. Oliver, R. Johnson, M. Capogna, J. Vikman, Z. Molnar, A. Babbs, C. J. Partridge, A. Salehi, M. Bengtsson, et al.
A dominant mutation in Snap25 causes impaired vesicle trafficking, sensorimotor gating, and ataxia in the blind-drunk mouse
PNAS,
February 13, 2007;
104(7):
2431 - 2436.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Thapar, M. O'Donovan, and M. J Owen
The genetics of attention deficit hyperactivity disorder
Hum. Mol. Genet.,
October 15, 2005;
14(suppl_2):
R275 - R282.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Zhang, A. P. Vilaythong, D. Yoshor, and J. L. Noebels
Elevated Thalamic Low-Voltage-Activated Currents Precede the Onset of Absence Epilepsy in the SNAP25-Deficient Mouse Mutant Coloboma
J. Neurosci.,
June 2, 2004;
24(22):
5239 - 5248.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. G. Honer, P. Falkai, T. A. Bayer, J. Xie, L. Hu, H.-Y. Li, V. Arango, J. J. Mann, A. J. Dwork, and W. S. Trimble
Abnormalities of SNARE Mechanism Proteins in Anterior Frontal Cortex in Severe Mental Illness
Cereb Cortex,
April 1, 2002;
12(4):
349 - 356.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L.-S. Chin, R. D. Nugent, M. C. Raynor, J. P. Vavalle, and L. Li
SNIP, a Novel SNAP-25-interacting Protein Implicated in Regulated Exocytosis
J. Biol. Chem.,
January 14, 2000;
275(2):
1191 - 1200.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. E. Arnold
Methyiphenidate vs. amphetamine: Comparative review
J Atten Disord,
January 1, 2000;
3(4):
200 - 211.
[Abstract]
[PDF]
|
 |
|
|